MovDisordV3, PascalFrancis, Corpus, bibRecord, 003368

Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study

Identifieur interne : 003368 ( PascalFrancis/Corpus ); précédent : 003367; suivant : 003369

Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study

Auteurs : R. Pahwa ; J. Marjama ; D. Mcguire ; K. Lyons ; F. Zwiebel ; P. Silverstein ; R. Ward ; W. C. Koller

Source :

Movement disorders [ 0885-3185 ] ; 1996.

RBID : Pascal:96-0334538

Descripteurs français

Pascal (Inist)
- Carbidopa, Lévodopa, Chimiothérapie, Antiparkinsonien, Efficacité traitement, Etude comparative, Parkinson maladie, Voie orale, Traitement, Pharmacocinétique, Homme, Produit générique.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Comparative study, Human, Levodopa, Oral administration, Parkinson disease, Pharmacokinetics, Treatment, Treatment efficiency.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 11`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study`
A11	`01`	`1`		`@1 PAHWA (R.)`
A11	`02`	`1`		`@1 MARJAMA (J.)`
A11	`03`	`1`		`@1 MCGUIRE (D.)`
A11	`04`	`1`		`@1 LYONS (K.)`
A11	`05`	`1`		`@1 ZWIEBEL (F.)`
A11	`06`	`1`		`@1 SILVERSTEIN (P.)`
A11	`07`	`1`		`@1 WARD (R.)`
A11	`08`	`1`		`@1 KOLLER (W. C.)`
A14	`01`			`@1 Department of Neurology, University of Kansas Medical Center @2 Kansas City, Kansas @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 8 aut.`
A20				`@1 427-430`
A21				`@1 1996`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000060104000100`
A44				`@0 0000 @1 © 1996 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 96-0334538`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Carbidopa @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @5 02`
C03	`02`	`X`	`ENG`	`@0 Levodopa @5 02`
C03	`02`	`X`	`SPA`	`@0 Levodopa @5 02`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 03`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 03`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 03`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 04`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 04`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 04`
C03	`05`	`X`	`FRE`	`@0 Efficacité traitement @5 05`
C03	`05`	`X`	`ENG`	`@0 Treatment efficiency @5 05`
C03	`05`	`X`	`SPA`	`@0 Eficacia tratamiento @5 05`
C03	`06`	`X`	`FRE`	`@0 Etude comparative @5 06`
C03	`06`	`X`	`ENG`	`@0 Comparative study @5 06`
C03	`06`	`X`	`GER`	`@0 Vergleich @5 06`
C03	`06`	`X`	`SPA`	`@0 Estudio comparativo @5 06`
C03	`07`	`X`	`FRE`	`@0 Parkinson maladie @5 07`
C03	`07`	`X`	`ENG`	`@0 Parkinson disease @5 07`
C03	`07`	`X`	`SPA`	`@0 Parkinson enfermedad @5 07`
C03	`08`	`X`	`FRE`	`@0 Voie orale @5 10`
C03	`08`	`X`	`ENG`	`@0 Oral administration @5 10`
C03	`08`	`X`	`SPA`	`@0 Vía oral @5 10`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`09`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`10`	`X`	`FRE`	`@0 Pharmacocinétique @5 18`
C03	`10`	`X`	`ENG`	`@0 Pharmacokinetics @5 18`
C03	`10`	`X`	`SPA`	`@0 Farmacocinética @5 18`
C03	`11`	`X`	`FRE`	`@0 Homme @5 20`
C03	`11`	`X`	`ENG`	`@0 Human @5 20`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`12`	`X`	`FRE`	`@0 Produit générique @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 53`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 53`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 53`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 54`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 54`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 54`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 55`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 55`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 55`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 56`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 56`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 56`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 57`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 57`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 57`
N21				`@1 232`

Format Inist (serveur)

NO :	PASCAL 96-0334538 INIST
ET :	Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study
AU :	PAHWA (R.); MARJAMA (J.); MCGUIRE (D.); LYONS (K.); ZWIEBEL (F.); SILVERSTEIN (P.); WARD (R.); KOLLER (W. C.)
AF :	Department of Neurology, University of Kansas Medical Center/Kansas City, Kansas/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 8 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1996; Vol. 11; No. 4; Pp. 427-430; Bibl. 23 ref.
LA :	Anglais
CC :	002B02B06
FD :	Carbidopa; Lévodopa; Chimiothérapie; Antiparkinsonien; Efficacité traitement; Etude comparative; Parkinson maladie; Voie orale; Traitement; Pharmacocinétique; Homme; Produit générique
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Levodopa; Chemotherapy; Antiparkinson agent; Treatment efficiency; Comparative study; Parkinson disease; Oral administration; Treatment; Pharmacokinetics; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
GD :	Vergleich; Aufbereiten
SD :	Levodopa; Quimioterapia; Antiparkinsoniano; Eficacia tratamiento; Estudio comparativo; Parkinson enfermedad; Vía oral; Tratamiento; Farmacocinética; Hombre
LO :	INIST-20953.354000060104000100
ID :	96-0334538

Links to Exploration step

Pascal:96-0334538

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study</title>
<author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marjama, J" sort="Marjama, J" uniqKey="Marjama J" first="J." last="Marjama">J. Marjama</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D." last="Mcguire">D. Mcguire</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K." last="Lyons">K. Lyons</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F." last="Zwiebel">F. Zwiebel</name>
</author>
<author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P." last="Silverstein">P. Silverstein</name>
</author>
<author><name sortKey="Ward, R" sort="Ward, R" uniqKey="Ward R" first="R." last="Ward">R. Ward</name>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0334538</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0334538 INIST</idno>
<idno type="RBID">Pascal:96-0334538</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003368</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study</title>
<author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marjama, J" sort="Marjama, J" uniqKey="Marjama J" first="J." last="Marjama">J. Marjama</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D." last="Mcguire">D. Mcguire</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K." last="Lyons">K. Lyons</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F." last="Zwiebel">F. Zwiebel</name>
</author>
<author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P." last="Silverstein">P. Silverstein</name>
</author>
<author><name sortKey="Ward, R" sort="Ward, R" uniqKey="Ward R" first="R." last="Ward">R. Ward</name>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Human</term>
<term>Levodopa</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Pharmacokinetics</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Carbidopa</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Efficacité traitement</term>
<term>Etude comparative</term>
<term>Parkinson maladie</term>
<term>Voie orale</term>
<term>Traitement</term>
<term>Pharmacocinétique</term>
<term>Homme</term>
<term>Produit générique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>11</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PAHWA (R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARJAMA (J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MCGUIRE (D.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LYONS (K.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ZWIEBEL (F.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SILVERSTEIN (P.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WARD (R.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KOLLER (W. C.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>427-430</s1>
</fA20>
<fA21><s1>1996</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000060104000100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1996 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>96-0334538</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="GER"><s0>Vergleich</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pharmacocinétique</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pharmacokinetics</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Farmacocinética</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Produit générique</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>53</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>53</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>54</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>54</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>55</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>55</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>55</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>56</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>56</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>56</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>57</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>57</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>57</s5>
</fC07>
<fN21><s1>232</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 96-0334538 INIST</NO>
<ET>Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study</ET>
<AU>PAHWA (R.); MARJAMA (J.); MCGUIRE (D.); LYONS (K.); ZWIEBEL (F.); SILVERSTEIN (P.); WARD (R.); KOLLER (W. C.)</AU>
<AF>Department of Neurology, University of Kansas Medical Center/Kansas City, Kansas/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1996; Vol. 11; No. 4; Pp. 427-430; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Carbidopa; Lévodopa; Chimiothérapie; Antiparkinsonien; Efficacité traitement; Etude comparative; Parkinson maladie; Voie orale; Traitement; Pharmacocinétique; Homme; Produit générique</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Levodopa; Chemotherapy; Antiparkinson agent; Treatment efficiency; Comparative study; Parkinson disease; Oral administration; Treatment; Pharmacokinetics; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<GD>Vergleich; Aufbereiten</GD>
<SD>Levodopa; Quimioterapia; Antiparkinsoniano; Eficacia tratamiento; Estudio comparativo; Parkinson enfermedad; Vía oral; Tratamiento; Farmacocinética; Hombre</SD>
<LO>INIST-20953.354000060104000100</LO>
<ID>96-0334538</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003368 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003368 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:96-0334538
   |texte=   Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study

Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri